Qu'est-ce que cela signifie pour ma pratique ?

The blocking of psilocybin-induced effects by both ketanserin and risperidone illustrate the role that 5-HT2 receptor agonism plays in the psilocybin-induced effects. A 0.25 mg/kg dose of psilocybin produces a psychotic syndrome which includes changes in mood, disturbances of sensory perception and thought processes and impaired ego-functioning. These changes are also observed in patients entering early schizoprenic stages. Psilocybin also produced spatial working memory deficits, similar to those seen in schizophrenic patients. These deficits were completely prevented by 5-HT2 antagonism but not dopamine receptor antagonism, further suggesting evidence for the role 5-HT2 receptor stimulation plays in both schizophrenic symptoms and psilocybin effects. The results are limited by the small sample size.